BCKDK Inhibitors Directly Antagonize Angiotensin II Type 1 Receptor and Induce Vasodilation Independently of BCAA Catabolism or BCKDK

The human body relies on a delicate balance of chemicals to keep blood flowing smoothly through its vast network of vessels. When this system falters, blood pressure can rise, straining the heart and increasing the risk of failure. For years, scientists have focused on a group of nutrients called branched-chain amino acids, which are essential building blocks found in protein-rich foods. In people with heart failure or metabolic diseases, levels of these amino acids often climb dangerously high. To fix this, researchers developed drugs designed to speed up the body's natural process of breaking down these amino acids, hoping that clearing them away would protect the heart. These drugs were thought to work by unlocking a specific enzyme, a molecular machine that controls how the body processes these nutrients.

However, a new study reveals that the story behind these drugs is far more complicated than originally believed. While the medications did lower blood pressure and relax blood vessels in mice, they did not do so by fixing the amino acid problem or by interacting with the enzyme they were designed to target. Instead, the researchers discovered that these drugs act like a master key for a completely different lock: a receptor on the surface of blood vessels that normally tightens them in response to a hormone called angiotensin II. By blocking this receptor directly, the drugs force the vessels to relax, a mechanism that has nothing to do with the amino acids they were intended to clear. This finding suggests that the heart benefits seen in previous studies may come from this unexpected side effect rather than the intended metabolic correction, raising important questions about how these drugs should be used in future treatments.

The journey to this discovery began with a simple observation that didn't fit the existing theory. Scientists had previously shown that drugs known as BCKDK inhibitors could lower blood pressure in mice, a result that seemed promising for treating heart failure. The prevailing idea was that these drugs worked by boosting the breakdown of branched-chain amino acids, thereby reducing the toxic buildup that damages the heart. But when the researchers looked closer at how the drugs affected blood vessels, the timeline didn't add up. The drugs caused vessels to widen almost instantly, within a minute of exposure. Such a rapid reaction suggested the drugs were acting directly on the muscle cells of the vessel walls, rather than through the slow, multi-step process of changing metabolism. To test this, they removed the blood vessels from mice and placed them in a chamber where they could measure tension. When they added the drugs, the vessels relaxed immediately, even when the researchers blocked the body's natural system for producing nitric oxide, a chemical that usually helps vessels widen. This proved the drugs were working through a direct, powerful mechanism that bypassed the body's usual chemical messengers.

To determine if the drugs were truly working by breaking down amino acids, the team turned to genetics. They created mice that lacked the specific enzyme, BCKDK, only in their smooth muscle cells, the tissue that controls blood vessel width. In these animals, the enzyme was gone, so the drugs had nothing to inhibit. If the drugs worked by targeting this enzyme, they should have had no effect on these mice. Yet, when the researchers tested the drugs on the blood vessels of these genetically modified mice, the vessels still relaxed just as strongly as they did in normal mice. The drugs worked perfectly well even without their intended target. The team went a step further, creating mice that could not break down amino acids at all in their muscle cells. Even in these animals, the drugs still lowered blood pressure. These experiments ruled out the possibility that the drugs were helping the heart by fixing amino acid metabolism. The drugs were clearly doing something else entirely.

The researchers then tested a different drug from the same class, one that was structurally different from the first two. This new drug was a potent inhibitor of the enzyme BCKDK, effectively stopping the breakdown of amino acids just as well as the others. However, when they gave this drug to mice or added it to blood vessels, nothing happened. The blood vessels did not relax, and blood pressure did not drop. This was a critical clue: simply inhibiting the enzyme was not enough to cause the beneficial effects. The drugs that worked shared a specific chemical shape, while the one that didn't work looked different. This pointed the scientists toward a different target, one that the working drugs could bind to but the non-working one could not.

Following this lead, the team focused on the angiotensin II type 1 receptor, a protein on blood vessel cells that is famous for causing vessels to tighten and blood pressure to rise. Drugs that block this receptor, known as ARBs, are a standard treatment for high blood pressure. The researchers suspected that the amino acid drugs might be accidentally blocking this receptor as well. Using computer models, they simulated how the drugs fit into the receptor's structure. The models showed that the working drugs fit snugly into the main binding pocket of the receptor, the same spot where natural hormones and standard blood pressure medications bind. They formed specific chemical connections with the receptor, locking it in a position where it could not send its "tighten up" signal. The drug that failed to lower blood pressure did not fit into this pocket at all. To confirm this, the researchers performed a physical experiment where they mixed the drug with the receptor and then tried to push it off using a standard blood pressure medication. The standard medication successfully displaced the drug, proving they were fighting for the same spot.

Finally, the team tested how the drug affected the receptor's behavior inside living cells. They found that when the drug was present, the receptor stopped responding to the hormone that normally triggers it. The hormone could not pull the receptor into the cell, could not recruit the helper proteins needed to send signals, and could not trigger the surge of calcium that makes muscles contract. The drug essentially silenced the receptor, preventing it from doing its job. The researchers also checked if the drug affected other similar receptors, such as those for vasopressin, a hormone that controls water balance. The drug did not block these other receptors, showing that its action was specific to the angiotensin receptor.

This study fundamentally changes the understanding of how these drugs work. The heart protection and blood pressure lowering seen in previous trials are likely due to the drug's ability to block the angiotensin receptor directly, not because it fixes the amino acid problem. This means that the drugs are acting as off-target blockers, a phenomenon where a medication hits a target it wasn't designed for. While this explains why the drugs work, it also raises questions about whether they offer any benefit beyond what existing blood pressure medications already provide. If the drugs are simply acting like standard blockers, patients might not need a new, expensive drug to achieve the same result. The findings serve as a reminder that small molecules can have complex, unexpected effects, and that understanding the true mechanism of a drug is essential before it is used to treat patients. The researchers conclude that future studies should carefully consider whether these drugs add any value when used alongside standard treatments, or if their effects are entirely redundant.